Imaging vascular physiology to monitor cancer treatment
- PMID: 16387510
- DOI: 10.1016/j.critrevonc.2005.10.006
Imaging vascular physiology to monitor cancer treatment
Abstract
The primary physiological function of the vasculature is to support perfusion, the nutritive flow of blood through the tissues. Vascular physiology can be studied non-invasively in human subjects using imaging methods such as positron emission tomography (PET), magnetic resonance imaging (MRI), X-ray computed tomography (CT), and Doppler ultrasound (DU). We describe the physiological rationale for imaging vascular physiology with these methods. We review the published data on repeatability. We review the literature on 'before-and-after' studies using these methods to monitor response to treatment in human subjects, in five broad clinical settings: (1) antiangiogenic agents, (2) vascular disruptive agents, (3) conventional cytotoxic drugs, (4) radiation treatment, and (5) agents affecting drug delivery. We argue that imaging of vascular physiology offers an attractive 'functional endpoint' for clinical trials of anticancer treatment. More conventional measures of tumour response, such as size criteria and the uptake of fluorodeoxyglucose, may be insensitive to therapeutically important changes in vascular function.
Similar articles
-
Tumor angiogenesis targeting using imaging agents.Q J Nucl Med. 2001 Jun;45(2):179-82. Q J Nucl Med. 2001. PMID: 11476168 Review.
-
Molecular imaging of antiangiogenic agents.Oncologist. 2005 Feb;10(2):92-103. doi: 10.1634/theoncologist.10-2-92. Oncologist. 2005. PMID: 15709211 Review.
-
Imaging the effects of anti-angiogenic treatments.Q J Nucl Med. 2003 Sep;47(3):163-70. Q J Nucl Med. 2003. PMID: 12897708 Review.
-
Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives.Crit Rev Oncol Hematol. 2009 Dec;72(3):217-38. doi: 10.1016/j.critrevonc.2008.07.012. Epub 2008 Aug 29. Crit Rev Oncol Hematol. 2009. PMID: 18760935 Review.
-
Imaging of angiogenesis: from microscope to clinic.Nat Med. 2003 Jun;9(6):713-25. doi: 10.1038/nm0603-713. Nat Med. 2003. PMID: 12778170 Review.
Cited by
-
Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine.Hepat Med. 2010 Aug 17;2:111-24. doi: 10.2147/HMER.S9052. Hepat Med. 2010. PMID: 24367211 Free PMC article. Review.
-
The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging.Mol Imaging. 2014;13:1-9. Mol Imaging. 2014. PMID: 24622811 Free PMC article.
-
Molecular and functional MRI of the tumor microenvironment.J Nucl Med. 2008 May;49(5):687-90. doi: 10.2967/jnumed.107.043349. Epub 2008 Apr 15. J Nucl Med. 2008. PMID: 18413382 Free PMC article. Review. No abstract available.
-
Novel agents in renal carcinoma: a reality check.Ther Adv Med Oncol. 2012 Jul;4(4):183-94. doi: 10.1177/1758834012443725. Ther Adv Med Oncol. 2012. PMID: 22754592 Free PMC article.
-
Dynamic contrast enhanced fluorescent molecular imaging of vascular disruption induced by combretastatin-A4P in tumor xenografts.J Biomed Nanotechnol. 2014 Aug;10(8):1545-51. doi: 10.1166/jbn.2014.1949. J Biomed Nanotechnol. 2014. PMID: 25016654 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical